Emerging Isotopes Pipeline Analysis and Global Market - Forecast to 2029
Emerging Isotopes Pipeline Analysis and Global Market - Forecast to 2029
Abstract
“Emerging Isotopes Pipeline Analysis and Global Market – Forecast to 2029” gives comprehensive insights on the various emerging isotope based candidates being developed for the both diagnosis as well as treatment of various cancers and non-cancer indications. The report covers marketed products details (Lutathera and Pluvito) and also candidates that are in various phases of development (Preclinical, Phase 1, Phase 2 & Phase 3). The pipeline focuses on diagnostic isotopes (Ga-68, Zr-89, Cu-64 and Pb-203) and therapeutic isotopes, (Ac-225, Pb-212, At-211, Ra-223, Th-227, Lu-177, Y-90, Re-188, Re-186, Cu-67, and Ho-166).
In case of Lu-177, Ga-68, Zr-89 and Cu-64, the report covers the patient population, treatment cost, total addressable market and penetration analysis for GEP-NET, Prostate cancer and Renal cancer. The pipeline analysis covers detailed analysis of name of candidates, list of companies, universities, and hospitals that are developing these agents, phase of development, nature of molecule, targets, and indications.
This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the emerging isotopes global market. The report also provides strategic insights on some of the molecules which will eventually be launched in the next few years.
Market Analysis
In market analysis, global GEP-NET, Prostate cancer and Renal cancer market are indicated along with the Ga-68, Cu-64 and Zr-89 diagnostics market, and Lu-177, therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Emerging Isotope is forecasted from 2020 to 2029.
Emerging Isotopes related deals analysis.
Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET, Prostate and Renal cancer).
Pipeline Analysis
Pipeline Analysis based Isotopes
Pipeline Analysis based on indications
Pipeline analysis based on targets
Pipeline analysis based on leading players
Key Players Analysis
The key player’s analysis section provides an in-depth understanding of various companies working on Emerging Isotopes and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
Key players overview
Key players Pipeline data (Pre-clinical, Phase 1, Phase 2 & Phase 3)
Key players deals (collaborations, partnership, licensing agreements, grants, funding etc.,)
“Emerging Isotopes Pipeline Analysis and Global Market – Forecast to 2029” gives comprehensive insights on the various emerging isotope based candidates being developed for the both diagnosis as well as treatment of various cancers and non-cancer indications. The report covers marketed products details (Lutathera and Pluvito) and also candidates that are in various phases of development (Preclinical, Phase 1, Phase 2 & Phase 3). The pipeline focuses on diagnostic isotopes (Ga-68, Zr-89, Cu-64 and Pb-203) and therapeutic isotopes, (Ac-225, Pb-212, At-211, Ra-223, Th-227, Lu-177, Y-90, Re-188, Re-186, Cu-67, and Ho-166).
In case of Lu-177, Ga-68, Zr-89 and Cu-64, the report covers the patient population, treatment cost, total addressable market and penetration analysis for GEP-NET, Prostate cancer and Renal cancer. The pipeline analysis covers detailed analysis of name of candidates, list of companies, universities, and hospitals that are developing these agents, phase of development, nature of molecule, targets, and indications.
This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the emerging isotopes global market. The report also provides strategic insights on some of the molecules which will eventually be launched in the next few years.
Market Analysis
In market analysis, global GEP-NET, Prostate cancer and Renal cancer market are indicated along with the Ga-68, Cu-64 and Zr-89 diagnostics market, and Lu-177, therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Emerging Isotope is forecasted from 2020 to 2029.
Emerging Isotopes related deals analysis.
Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET, Prostate and Renal cancer).
Pipeline Analysis
Pipeline Analysis based Isotopes
Pipeline Analysis based on indications
Pipeline analysis based on targets
Pipeline analysis based on leading players
Key Players Analysis
The key player’s analysis section provides an in-depth understanding of various companies working on Emerging Isotopes and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
Key players overview
Key players Pipeline data (Pre-clinical, Phase 1, Phase 2 & Phase 3)
Key players deals (collaborations, partnership, licensing agreements, grants, funding etc.,)
Content
Table of Contents
1 EXECUTIVE SUMMARY 14
2 INTRODUCTION 21
2.1 REPORT SCOPE 21
2.2 REPORT DESCRIPTION 21
2.3 PIPELINE ANALYSIS 22
2.4 KEY PLAYERS ANALYSIS 22
2.5 STAKEHOLDERS 22
2.6 RESEARCH METHODOLOGY 23
3 EMERGING ISOTOPES 24
3.1 INTRODUCTION 24
3.2 PIPELINE ANALYSIS OVERVIEW 24
3.2.1 DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS 35
3.2.2 THERAPEUTIC ISOTOPES PIPELINE ANALYSIS 42
3.3 DEMAND ANALYSIS OF EMERGING ISOTOPES 51
3.4 LUTETIUM (Lu-177) 52
3.4.1 GEP-NET MARKET ANALYSIS 54
3.4.2 PROSTATE CANCER MARKET ANALYSIS 65
3.4.3 LUTETIUM PIPELINE ANALYSIS 76
3.4.3.1 Demand and Production Analysis of Lutetium-177 (Lu-177) 91
3.4.4 Lu-177 – DEALS, APPROVALS, AND FUNDING 95
3.5 GALLIUM (Ga-68) 103
3.5.1 SUPPLY CHAIN ANALYSIS OF GALLIUM-68 (Ga-68) 106
3.5.2 Ga-68 MARKET 108
3.5.3 GALLIUM-68 (Ga-68) PIPELINE ANALYSIS 113
3.5.4 Ga-68 – DEALS, APPROVALS, AND FUNDING 122
3.6 ACTINIUM (Ac-225) 128
3.6.1 PRODUCTION ANALYSIS OF ACTINIUM-225 (Ac-225) AND
BISMUTH-213 (Bi-213) 130
3.6.2 ACTINIUM (Ac-225) PIPELINE ANALYSIS 133
3.6.3 Ac-225 – DEALS, APPROVALS, AND FUNDING 139
3.7 YTTRIUM (Y-90) 145
3.7.1 YTTRIUM (Y-90) PIPELINE ANALYSIS 148
3.7.2 Y-90 – DEALS, APPROVALS, AND FUNDING 154
3.8 ZIRCONIUM (Zr-89) 156
3.8.1 ZIRCONIUM (Zr-89) PIPELINE ANALYSIS 160
3.8.2 Zr-89 – DEALS, APPROVALS, AND FUNDING 167
3.9 LEAD (Pb-212)/BISMUTH (Bi-212) 169
3.9.1 LEAD (Pb-212) PIPELINE ANALYSIS 170
3.9.2 Pb-212 – DEALS, APPROVALS, AND FUNDING 175
3.10 COPPER (Cu-64) 178
3.10.1 COPPER 64 (Cu-64) PIPELINE ANALYSIS 182
3.10.2 Cu-64 – DEALS, APPROVALS, AND FUNDING 190
3.11 COPPER (Cu-67) 191
3.11.1 COPPER 67 (Cu-67) PIPELINE ANALYSIS 192
3.11.2 Cu-67 – DEALS, APPROVALS, NEWS, AND FUNDING 193
3.12 RHENIUM (Re-186) 196
3.12.1 RHENIUM (Re-186) PIPELINE ANALYSIS 198
3.12.2 Re-186 – DEALS, APPROVALS, NEWS, AND FUNDING 199
3.13 RHENIUM-188 (Re-188) 201
3.13.1 RHENIUM (Re-188) PIPELINE ANALYSIS 201
3.13.2 Re-188 – DEALS, APPROVALS, NEWS, AND FUNDING 202
3.14 ASTATINE (At-211) 203
3.14.1 ASTATINE (At-211) PIPELINE ANALYSIS 206
3.14.2 At-211 – DEALS, APPROVALS, NEWS, AND FUNDING 207
3.15 HOLMIUM (Ho-166) 209
3.15.1 HOLMIUM (Ho-166) PIPELINE ANALYSIS 210
3.15.2 Ho-166 – DEALS, APPROVALS, AND NEWS 210
3.16 RADIUM (Ra-223) 211
3.16.1 SUPPLY CHAIN ANALYSIS OF RADIUM-223 (Ra-223) 212
3.16.2 RADIUM (Ra-223) PIPELINE ANALYSIS 213
3.17 RADIUM (Ra-224) 214
3.17.1 RADIUM (Ra-224) PIPELINE ANALYSIS 214
3.17.2 Ra-224 – DEALS, APPROVALS, NEWS, AND FUNDING 214
3.18 THORIUM (Th-227) 215
3.18.1 THORIUM (Th-227) PIPELINE ANALYSIS 216
3.19 SCANDIUM (Sc-43, 44, 47) 216
3.20 TERBIUM (Tb-149,152,155, 161) 218
3.21 ARSENIC (As-72, As-74, As-77) 220
3.22 IRON (Fe-52) 220
3.23 BARIUM-128 (Ba-128) 221
3.24 BARIUM-131 (Ba-131) 221
4 MAJOR PLAYER PROFILES 222
4.1 BOSTON SCIENTIFIC CORPORATION (BSC) 222
4.2 CLARITY PHARMACEUTICALS LIMITED 223
4.3 CURIUM SAS 224
4.4 ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
(PENTIXAPHARM, GMBH) 225
4.5 FUSION PHARMACEUTICALS, INC. 226
4.6 ITM ISOTOPE TECHNOLOGIES MUNICH SE 227
4.7 NOVARTIS AG 228
4.8 ORANO MED, LLC 229
4.9 PLUS THEAPEUTICS, INC. 230
4.10 POINT BIOPHARMA GLOBAL, INC., 231
4.11 RADIOMEDIX, INC., 232
4.12 TELIX PHARMACEUTICALS, LTD. 233
In case of Lu-177, Ga-68, Zr-89 and Cu-64, the report covers the patient population, treatment cost, total addressable market and penetration analysis for GEP-NET, Prostate cancer and Renal cancer. The pipeline analysis covers detailed analysis of name of candidates, list of companies, universities, and hospitals that are developing these agents, phase of development, nature of molecule, targets, and indications.
This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the emerging isotopes global market. The report also provides strategic insights on some of the molecules which will eventually be launched in the next few years.
Market Analysis
In market analysis, global GEP-NET, Prostate cancer and Renal cancer market are indicated along with the Ga-68, Cu-64 and Zr-89 diagnostics market, and Lu-177, therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Emerging Isotope is forecasted from 2020 to 2029.
Emerging Isotopes related deals analysis.
Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET, Prostate and Renal cancer).
Pipeline Analysis
Pipeline Analysis based Isotopes
Pipeline Analysis based on indications
Pipeline analysis based on targets
Pipeline analysis based on leading players
Key Players Analysis
The key player’s analysis section provides an in-depth understanding of various companies working on Emerging Isotopes and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
Key players overview
Key players Pipeline data (Pre-clinical, Phase 1, Phase 2 & Phase 3)
Key players deals (collaborations, partnership, licensing agreements, grants, funding etc.,)
“Emerging Isotopes Pipeline Analysis and Global Market – Forecast to 2029” gives comprehensive insights on the various emerging isotope based candidates being developed for the both diagnosis as well as treatment of various cancers and non-cancer indications. The report covers marketed products details (Lutathera and Pluvito) and also candidates that are in various phases of development (Preclinical, Phase 1, Phase 2 & Phase 3). The pipeline focuses on diagnostic isotopes (Ga-68, Zr-89, Cu-64 and Pb-203) and therapeutic isotopes, (Ac-225, Pb-212, At-211, Ra-223, Th-227, Lu-177, Y-90, Re-188, Re-186, Cu-67, and Ho-166).
In case of Lu-177, Ga-68, Zr-89 and Cu-64, the report covers the patient population, treatment cost, total addressable market and penetration analysis for GEP-NET, Prostate cancer and Renal cancer. The pipeline analysis covers detailed analysis of name of candidates, list of companies, universities, and hospitals that are developing these agents, phase of development, nature of molecule, targets, and indications.
This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the emerging isotopes global market. The report also provides strategic insights on some of the molecules which will eventually be launched in the next few years.
Market Analysis
In market analysis, global GEP-NET, Prostate cancer and Renal cancer market are indicated along with the Ga-68, Cu-64 and Zr-89 diagnostics market, and Lu-177, therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Emerging Isotope is forecasted from 2020 to 2029.
Emerging Isotopes related deals analysis.
Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET, Prostate and Renal cancer).
Pipeline Analysis
Pipeline Analysis based Isotopes
Pipeline Analysis based on indications
Pipeline analysis based on targets
Pipeline analysis based on leading players
Key Players Analysis
The key player’s analysis section provides an in-depth understanding of various companies working on Emerging Isotopes and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
Key players overview
Key players Pipeline data (Pre-clinical, Phase 1, Phase 2 & Phase 3)
Key players deals (collaborations, partnership, licensing agreements, grants, funding etc.,)
1 EXECUTIVE SUMMARY 14
2 INTRODUCTION 21
2.1 REPORT SCOPE 21
2.2 REPORT DESCRIPTION 21
2.3 PIPELINE ANALYSIS 22
2.4 KEY PLAYERS ANALYSIS 22
2.5 STAKEHOLDERS 22
2.6 RESEARCH METHODOLOGY 23
3 EMERGING ISOTOPES 24
3.1 INTRODUCTION 24
3.2 PIPELINE ANALYSIS OVERVIEW 24
3.2.1 DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS 35
3.2.2 THERAPEUTIC ISOTOPES PIPELINE ANALYSIS 42
3.3 DEMAND ANALYSIS OF EMERGING ISOTOPES 51
3.4 LUTETIUM (Lu-177) 52
3.4.1 GEP-NET MARKET ANALYSIS 54
3.4.2 PROSTATE CANCER MARKET ANALYSIS 65
3.4.3 LUTETIUM PIPELINE ANALYSIS 76
3.4.3.1 Demand and Production Analysis of Lutetium-177 (Lu-177) 91
3.4.4 Lu-177 – DEALS, APPROVALS, AND FUNDING 95
3.5 GALLIUM (Ga-68) 103
3.5.1 SUPPLY CHAIN ANALYSIS OF GALLIUM-68 (Ga-68) 106
3.5.2 Ga-68 MARKET 108
3.5.3 GALLIUM-68 (Ga-68) PIPELINE ANALYSIS 113
3.5.4 Ga-68 – DEALS, APPROVALS, AND FUNDING 122
3.6 ACTINIUM (Ac-225) 128
3.6.1 PRODUCTION ANALYSIS OF ACTINIUM-225 (Ac-225) AND
BISMUTH-213 (Bi-213) 130
3.6.2 ACTINIUM (Ac-225) PIPELINE ANALYSIS 133
3.6.3 Ac-225 – DEALS, APPROVALS, AND FUNDING 139
3.7 YTTRIUM (Y-90) 145
3.7.1 YTTRIUM (Y-90) PIPELINE ANALYSIS 148
3.7.2 Y-90 – DEALS, APPROVALS, AND FUNDING 154
3.8 ZIRCONIUM (Zr-89) 156
3.8.1 ZIRCONIUM (Zr-89) PIPELINE ANALYSIS 160
3.8.2 Zr-89 – DEALS, APPROVALS, AND FUNDING 167
3.9 LEAD (Pb-212)/BISMUTH (Bi-212) 169
3.9.1 LEAD (Pb-212) PIPELINE ANALYSIS 170
3.9.2 Pb-212 – DEALS, APPROVALS, AND FUNDING 175
3.10 COPPER (Cu-64) 178
3.10.1 COPPER 64 (Cu-64) PIPELINE ANALYSIS 182
3.10.2 Cu-64 – DEALS, APPROVALS, AND FUNDING 190
3.11 COPPER (Cu-67) 191
3.11.1 COPPER 67 (Cu-67) PIPELINE ANALYSIS 192
3.11.2 Cu-67 – DEALS, APPROVALS, NEWS, AND FUNDING 193
3.12 RHENIUM (Re-186) 196
3.12.1 RHENIUM (Re-186) PIPELINE ANALYSIS 198
3.12.2 Re-186 – DEALS, APPROVALS, NEWS, AND FUNDING 199
3.13 RHENIUM-188 (Re-188) 201
3.13.1 RHENIUM (Re-188) PIPELINE ANALYSIS 201
3.13.2 Re-188 – DEALS, APPROVALS, NEWS, AND FUNDING 202
3.14 ASTATINE (At-211) 203
3.14.1 ASTATINE (At-211) PIPELINE ANALYSIS 206
3.14.2 At-211 – DEALS, APPROVALS, NEWS, AND FUNDING 207
3.15 HOLMIUM (Ho-166) 209
3.15.1 HOLMIUM (Ho-166) PIPELINE ANALYSIS 210
3.15.2 Ho-166 – DEALS, APPROVALS, AND NEWS 210
3.16 RADIUM (Ra-223) 211
3.16.1 SUPPLY CHAIN ANALYSIS OF RADIUM-223 (Ra-223) 212
3.16.2 RADIUM (Ra-223) PIPELINE ANALYSIS 213
3.17 RADIUM (Ra-224) 214
3.17.1 RADIUM (Ra-224) PIPELINE ANALYSIS 214
3.17.2 Ra-224 – DEALS, APPROVALS, NEWS, AND FUNDING 214
3.18 THORIUM (Th-227) 215
3.18.1 THORIUM (Th-227) PIPELINE ANALYSIS 216
3.19 SCANDIUM (Sc-43, 44, 47) 216
3.20 TERBIUM (Tb-149,152,155, 161) 218
3.21 ARSENIC (As-72, As-74, As-77) 220
3.22 IRON (Fe-52) 220
3.23 BARIUM-128 (Ba-128) 221
3.24 BARIUM-131 (Ba-131) 221
4 MAJOR PLAYER PROFILES 222
4.1 BOSTON SCIENTIFIC CORPORATION (BSC) 222
4.2 CLARITY PHARMACEUTICALS LIMITED 223
4.3 CURIUM SAS 224
4.4 ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
(PENTIXAPHARM, GMBH) 225
4.5 FUSION PHARMACEUTICALS, INC. 226
4.6 ITM ISOTOPE TECHNOLOGIES MUNICH SE 227
4.7 NOVARTIS AG 228
4.8 ORANO MED, LLC 229
4.9 PLUS THEAPEUTICS, INC. 230
4.10 POINT BIOPHARMA GLOBAL, INC., 231
4.11 RADIOMEDIX, INC., 232
4.12 TELIX PHARMACEUTICALS, LTD. 233
Related Report
